Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.

Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter of 2022 and provided an update on the Company's business operations and clinical development programs. “We are pleased to have recently completed rolling submission of a New Drug Application (“NDA”) for omaveloxolone for the treatment of patients with Friedreich's ataxia in th

Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

Bausch Health Companies Inc

Catalyst Pharmaceuticals

Epizyme

Exelixis

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2022, and provide an update on the Company's business operations and clinical development programs on May 10, 2022, before the U.S. financial markets open. Conference Call Information Reata's management will host a conference call on May 10,

Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same.

Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for omaveloxolone for the treatment of patients with Friedreich's ataxia. This NDA is supported by the efficacy and safety data from the MOXIe Part 1, Part 2, and MOXIe Extension studies. The

Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?

Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?

New York, New York--(Newsfile Corp. - March 15, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own RETA please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The...

Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm

Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.

Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y

Reata Pharmaceuticals Inc.'s (RETA) CEO Warren Huff on Q4 2021 Results - Earnings Call Transcript

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter and full year ended on December 31, 2021 and provided an update on the Company's business operations and clinical development programs. “We are making important progress in our efforts to advance omaveloxolone for the treatment of patients with Friedreich's ataxia (‘FA') including r

Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome. The CRL indicates that the FDA cannot approve the NDA in its present form. Based on its review, the FD

Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q4 Earnings Expected to Decline

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 18, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and reminds investors of the February 18, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Reata stock or options...

Reata Update

New York, New York--(Newsfile Corp. - February 18, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, 2021, inclusive (the "Class Period"), of the important February 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased Reata Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of...

FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses Over $100K to Secure Counsel Before Important February 18 Deadline in Securities Class Action - RETA

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/reata-pharmaceuticals-inc-loss-submission-form-2/?id=23798&from=4 This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Reata securities, and/or sold Reata put options, between November 9, 2020 and December 8, 2021, inclusive.

RETA SHAREHOLDER ALERT: Jakubowitz Law Reminds Reata Shareholders of a Lead Plaintiff Deadline of February 18, 2022

NEW YORK , Feb. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, 2021, inclusive (the "Class Period"), of the important February 18, 2022 lead plaintiff deadline. SO WHAT: If you purchased Reata Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

RETA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reata Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - RETA

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on the Company's business operations and clinical development programs pre-market on February 28, 2022. Conference Call Information Reata's management will host a conference call on February 28, 2022, at 8:30 a.m. ET. The conference call will be accessible

Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 17, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and reminds investors of the February 18, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Reata stock or...

Reata Class Action Reminder

Boston, Massachusetts--(Newsfile Corp. - February 17, 2022) - The Thornton Law Firm reminds investors that a class action lawsuit has been filed on behalf of investors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The case is currently in the lead plaintiff stage. Investors who purchased Reata securities on or after November 14, 2016, may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Reata-Pharmaceuticals-Inc for more information. Investors may also email investors@tenlaw.com or call 617-531-3917....

RETA INVESTOR ALERT: Thornton Law Firm Reminds Reata Pharmaceuticals Investors of Important Deadline for Securities Class Action Lawsuit

San Francisco, California--(Newsfile Corp. - February 17, 2022) -  Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: Nov. 9, 2020 - Dec. 8, 2021Lead Plaintiff Deadline: Feb. 18, 2022Visit: www.hbsslaw.com/investor-fraud/RETA Contact An Attorney Now: RETA@hbsslaw.com 844-916-0895Reata Pharmaceuticals, Inc. (RETA) Securities Fraud...

RETA INVESTOR DEADLINE TOMRROW: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm's Attorneys Now

Los Angeles, California--(Newsfile Corp. - February 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

News for Reata Pharmaceuticals Stock (RETA)